Principal Investigators

The CTUs Principal Investigators from left to right: Dr. Jeffrey Lennox and Dr. Carlos del Rio

Carlos del Rio, MD

Dr. del Rio is the leader of the Atlanta Ponce Clinical Research Site. He is a Distinguished Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine and Executive Associate Dean for Emory at Grady.  He is also Professor of Global Health in the Department of Global Health and Professor of Epidemiology at the Rollins School of Public Health. He is also co-Director of the Emory Center for AIDS Research (CFAR) and co-PI of the Emory-CDC Clinical Trials Unit and the Emory Vaccine and Treatment Evalaution Unit. Dr. del Rio is a native of Mexico where he attended medical school at Universidad La Salle, graduating in 1983.  He did his Internal Medicine and Infectious Diseases residencies at Emory University.

Jeffrey Lennox, MD

Dr. Lennox is Professor of Medicine at Emory University School of Medicine, Associate Dear for Clinical Research, and Vice Chair for Grady Affairs for the Department of Medicine. His leadership in the Emory Healthcare Clinical Trials Unit has ensured successful recruitment and retention of minorities and women into clinical trials. He is also testing new pharmaceutical and immunologic therapies for acute and chronic HIV infection. In addition, my research unit tests strategies for the management of complications of HIV infection or of antiretroviral therapy. Much of this research is done in conjunction with the NIH-funded AIDS Clinical Trials Group, for which I am the Principal Investigator of the Emory-CDC Clinical Trials Unit. I am also working with younger faculty as a mentor to investigate the predictors of success of antiretroviral therapy.

Dr. Lennox is also a member of the Co-Infections and Malignancies Committee of the AIDS Clinical Trials Group (ACTG), serves as an external consultant to the Oral HIV/AIDS Research Alliance Network, and is involved in an international study investigating the in vivo anti-malarial activity of an HIV-1 protease inhibitor.